Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Research | December 09, 2025 | December 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 09, 2025 · Filed December 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,833 |
Reported balance
After 2025-12-09 transaction · row 1
1 source rowRow 1 · 2025-12-09 · Tax withholding · Disposed 4,229 · Balance 47,833 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 4,375 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,375 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 434 | $630.41 | $273,597.94 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,323 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 434 shares of Company stock on February 15, 2022 at prices ranging from $630.18 to $630.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 15, 2022 at each separate price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 533 | $629.35 | $335,443.55 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,757 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 533 shares of Company stock on February 15, 2022 at prices ranging from $629.00 to $629.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 15, 2022 at each separate price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 520 | $628.62 | $326,882.40 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,290 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 520 shares of Company stock on February 15, 2022 at prices ranging from $628.09 to $628.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 15, 2022 at each separate price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 630 | $627.49 | $395,318.70 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,810 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 630 shares of Company stock on February 15, 2022 at prices ranging from $627.00 to $627.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 15, 2022 at each separate price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 421 | $626.51 | $263,760.71 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,440 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 421 shares of Company stock on February 15, 2022 at prices ranging from $626.08 to $626.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 15, 2022 at each separate price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 50 | $625.90 | $31,295.00 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,861 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 99 | $622.09 | $61,586.91 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,911 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 99 shares of Company stock on February 15, 2022 at prices ranging from $622.00 to $622.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 15, 2022 at each separate price. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · derivative · entry 15 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 6,460 | $626.79 | $4,049,063.40 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,010 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 10,000 | $179.13 | $1,791,300.00 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 11, 2021 Filed Dec 14, 2021 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 697 | $664.34 | $463,044.98 |
DisclosureSEC source: 0001708138-21-000105 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,470 Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 38 | $672.30 | $25,547.40 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 19 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,167 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 219 | $671.33 | $147,021.27 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 18 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,205 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · price: Represents volume-weighted average price of sales of 219 shares of Company stock on December 10, 2021 at prices ranging from $671.19 to $671.39. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 872 | $670.68 | $584,832.96 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 17 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,424 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · price: Represents volume-weighted average price of sales of 872 shares of Company stock on December 10, 2021 at prices ranging from $670.11 to $670.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,018 | $669.60 | $681,652.80 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 16 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,296 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 1,018 shares of Company stock on December 10, 2021 at prices ranging from $669.03 to $669.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,738 | $668.42 | $1,161,713.96 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 15 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,314 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 1,738 shares of Company stock on December 10, 2021 at prices ranging from $668.10 to $668.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 280 | $667.50 | $186,900.00 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 14 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,052 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 280 shares of Company stock on December 10, 2021 at prices ranging from $667.01 to $667.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 384 | $666.40 | $255,897.60 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 13 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,332 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 384 shares of Company stock on December 10, 2021 at prices ranging from $666.06 to $666.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 404 | $665.29 | $268,777.16 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 12 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,716 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 404 shares of Company stock on December 10, 2021 at prices ranging from $665.03 to $665.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 158 | $664.28 | $104,956.24 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,120 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 158 shares of Company stock on December 10, 2021 at prices ranging from $664.06 to $664.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 272 | $663.61 | $180,501.92 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 10 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,278 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 272 shares of Company stock on December 10, 2021 at prices ranging from $663.14 to $663.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 354 | $662.36 | $234,475.44 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,550 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 354 shares of Company stock on December 10, 2021 at prices ranging from $662.06 to $662.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 282 | $661.57 | $186,562.74 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,904 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 282 shares of Company stock on December 10, 2021 at prices ranging from $661.27 to $661.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $660.45 | $2,641.80 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,186 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on December 10, 2021 at prices ranging from $660.38 to $660.47. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 370 | $659.29 | $243,937.30 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,190 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 370 shares of Company stock on December 10, 2021 at prices ranging from $659.29 to $659.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 330 | $658.78 | $217,397.40 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,560 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 330 shares of Company stock on December 10, 2021 at prices ranging from $658.02 to $658.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 399 | $657.61 | $262,386.39 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,890 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 399 shares of Company stock on December 10, 2021 at prices ranging from $657.27 to $657.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 10, 2021 at each separate price. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · derivative · entry 21 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,500 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F18 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 9,378 | $657.11 | $6,162,377.58 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,289 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 16,500 | $52.03 | $858,495.00 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 14,783 | $0.00 Strike: $644.54 | $0.00 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · derivative · entry 22 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,783 Underlying: Common Stock · 14,783 shares Expires 2031-12-08 F18 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 23:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 3,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000098 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,167 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2023 and 50% on December 8, 2025. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 67 | $660.32 | $44,241.44 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 20 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,705 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 155 | $659.15 | $102,168.25 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 19 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,772 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 155 shares of Company stock on November 16, 2021 at prices ranging from $659.01 to $659.30. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 71 | $658.56 | $46,757.76 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 18 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,927 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 74 | $657.46 | $48,652.04 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 17 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,998 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 92 | $655.30 | $60,287.60 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 16 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,072 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 92 shares of Company stock on November 16, 2021 at prices ranging from $655.20 to $655.31. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 198 | $654.34 | $129,559.32 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 15 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,164 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 198 shares of Company stock on November 16, 2021 at prices ranging from $654.07 to $654.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 454 | $653.31 | $296,602.74 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 14 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,362 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 454 shares of Company stock on November 16, 2021 at prices ranging from $653.04 to $653.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 133 | $652.24 | $86,747.92 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 13 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,816 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 133 shares of Company stock on November 16, 2021 at prices ranging from $652.22 to $652.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 296 | $651.42 | $192,820.32 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 12 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,949 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 296 shares of Company stock on November 16, 2021 at prices ranging from $651.00 to $651.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $649.26 | $3,246.30 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,245 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 86 | $648.20 | $55,745.20 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 10 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,250 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 86 shares of Company stock on November 16, 2021 at prices ranging from $648.15 to $648.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 844 | $647.39 | $546,397.16 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,336 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 844 shares of Company stock on November 16, 2021 at prices ranging from $647.09 to $647.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 557 | $646.52 | $360,111.64 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,180 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 557 shares of Company stock on November 16, 2021 at prices ranging from $646.12 to $646.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,640 | $645.41 | $1,058,472.40 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,737 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 1,640 shares of Company stock on November 16, 2021 at prices ranging from $645.01 to $645.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,106 | $644.71 | $713,049.26 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,377 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 1,106 shares of Company stock on November 16, 2021 at prices ranging from $644.24 to $644.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 924 | $643.42 | $594,520.08 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,483 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 924 shares of Company stock on November 16, 2021 at prices ranging from $643.07 to $643.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 465 | $642.76 | $298,883.40 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,407 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 465 shares of Company stock on November 16, 2021 at prices ranging from $642.35 to $642.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,579 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-21-000086 · edgardoc.xml · derivative · entry 22 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,579 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.